135 related articles for article (PubMed ID: 19320280)
1. Ondansetron: design and development of oral pharmaceutical suspensions.
Gallardo Lara V; Gallardo ML; Morales Hernandez ME; Ruiz Martinez MA
Pharmazie; 2009 Feb; 64(2):90-3. PubMed ID: 19320280
[TBL] [Abstract][Full Text] [Related]
2. Physical characteristics of polymer complexes in suspension obtained from cellulosic latexes with ondansetron.
Ruiz A; Llácer JM; Morales E; Gallardo V
J Mater Sci Mater Med; 2004 Jun; 15(6):659-64. PubMed ID: 15346732
[TBL] [Abstract][Full Text] [Related]
3. Development of chitosan-based ondansetron buccal delivery system for the treatment of emesis.
Park DM; Song YK; Jee JP; Kim HT; Kim CK
Drug Dev Ind Pharm; 2012 Sep; 38(9):1077-83. PubMed ID: 22182584
[TBL] [Abstract][Full Text] [Related]
4. Sustained release formulation of Ondansetron HCl using osmotic drug delivery approach.
Gundu R; Pekamwar S; Shelke S; Shep S; Kulkarni D
Drug Dev Ind Pharm; 2020 Mar; 46(3):343-355. PubMed ID: 31937128
[TBL] [Abstract][Full Text] [Related]
5. Adsorption-desorption of ondansetron on latex particles.
Llácer JM; Ruiz MA; Parera A; Gallardo V
Drug Dev Ind Pharm; 2000 Mar; 26(3):237-42. PubMed ID: 10738640
[TBL] [Abstract][Full Text] [Related]
6. X-ray diffraction and electron microscopy in the polymorphism study of ondansetron hydrochloride.
Llácer JM; Gallardo V; Delgado R; Párraga J; Martin D; Ruiz MA
Drug Dev Ind Pharm; 2001 Oct; 27(9):899-908. PubMed ID: 11763467
[TBL] [Abstract][Full Text] [Related]
7. Stability of ondansetron and dexamethasone infusion upon refrigeration.
Rolin C; Hecq JD; Vanbeckbergen DF; Jamart J; Galanti LM
Ann Pharmacother; 2011 Jan; 45(1):130-1. PubMed ID: 21156815
[No Abstract] [Full Text] [Related]
8. Formulation and evaluation of ondansetron nasal delivery systems.
Cho E; Gwak H; Chun I
Int J Pharm; 2008 Feb; 349(1-2):101-7. PubMed ID: 17822864
[TBL] [Abstract][Full Text] [Related]
9. A technical feasibility study of surfactant-free drug suspensions using octenyl succinate-modified starches.
Kuentz M; Egloff P; Röthlisberger D
Eur J Pharm Biopharm; 2006 May; 63(1):37-43. PubMed ID: 16356701
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical development of ondansetron injection.
Leak RE; Woodford JD
Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S67-9. PubMed ID: 2533902
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, multicenter trial comparing transdermal scopolamine plus ondansetron to ondansetron alone for the prevention of postoperative nausea and vomiting in the outpatient setting.
Gan TJ; Sinha AC; Kovac AL; Jones RK; Cohen SA; Battikha JP; Deutsch JS; Pergolizzi JV; ; Glass PS
Anesth Analg; 2009 May; 108(5):1498-504. PubMed ID: 19372328
[TBL] [Abstract][Full Text] [Related]
12. Comparative pharmacokinetic studies of fast dissolving film and oral solution of ondansetron in rats.
Choudhary DR; Patel VA; Chhalotiya UK; Patel HV; Kundawala AJ
Curr Drug Deliv; 2013 Dec; 10(6):696-700. PubMed ID: 23755722
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of buccal bioadhesive tablet of an anti-emetic agent ondansetron.
Hassan N; Khar RK; Ali M; Ali J
AAPS PharmSciTech; 2009; 10(4):1085-92. PubMed ID: 19757080
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of orally disintegrating ondansetron in preventing postoperative nausea and vomiting after laparoscopic cholecystectomy: a randomised, double-blind placebo controlled study.
Grover VK; Mathew PJ; Hegde H
Anaesthesia; 2009 Jun; 64(6):595-600. PubMed ID: 19453311
[TBL] [Abstract][Full Text] [Related]
15. Design and evaluation of buccal films as paediatric dosage form for transmucosal delivery of ondansetron.
Trastullo R; Abruzzo A; Saladini B; Gallucci MC; Cerchiara T; Luppi B; Bigucci F
Eur J Pharm Biopharm; 2016 Aug; 105():115-21. PubMed ID: 27267732
[TBL] [Abstract][Full Text] [Related]
16. Preparation of an oil suspension containing ondansetron hydrochloride as a sustained release parenteral formulation.
Nguyen TT; Duong VA; Maeng HJ; Chi SC
Drug Deliv Transl Res; 2020 Feb; 10(1):282-295. PubMed ID: 31659599
[TBL] [Abstract][Full Text] [Related]
17. Experimental designed optimisation and stability evaluation of dry suspensions with artemisinin derivatives for paediatric use.
Gabriëls M; Plaizier-Vercammen J
Int J Pharm; 2004 Sep; 283(1-2):19-34. PubMed ID: 15363498
[TBL] [Abstract][Full Text] [Related]
18. Precipitation of ondansetron in alkaline solutions.
Jarosinski PF; Hirschfeld S
N Engl J Med; 1991 Oct; 325(18):1315-6. PubMed ID: 1656257
[No Abstract] [Full Text] [Related]
19. Stability of fenbendazole suspensions for veterinary use. Correlation between zeta potential and sedimentation.
Arias JL; López-Viota M; Clares B; Ruiz MA
Eur J Pharm Sci; 2008 Aug; 34(4-5):257-62. PubMed ID: 18539013
[TBL] [Abstract][Full Text] [Related]
20. Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags.
Stewart JT; Warren FW; King DT; Venkateshwaran TG; Ponder GW; Fox JL
Am J Health Syst Pharm; 1997 Apr; 54(8):915-20. PubMed ID: 9114924
[No Abstract] [Full Text] [Related]
[Next] [New Search]
